Clinuvel posts annual report, governance update

Q: What is the purpose of Clinuvel Pharmaceuticals Ltd (CUVL) Form 6-K filed in August 2026?

The Form 6-K furnishes ASX-filed materials to U.S. investors, including the annual report, corporate governance disclosures, an Appendix 4G, an investor presentation, and three press releases, all dated around August 27, 2026.

Q: Which key documents did CUVL include with this Form 6-K?

Clinuvel included its Annual Report (Exhibit 99.1), Corporate Governance Disclosure (99.2), Appendix 4G (99.3), an investor Presentation (99.4), and three press releases (99.5–99.7).

Q: What is Clinuvel Pharmaceuticals Ltd’s reporting status in this Form 6-K?

Clinuvel is identified as a foreign private issuer and indicates that it files annual reports under cover of Form 20-F, rather than Form 40-F.

Q: Does this CUVL Form 6-K itself provide financial results?

The Form 6-K itself does not detail financial results; it forwards the Annual Report and related ASX documents as exhibits for investors seeking financial and corporate governance information.

Clinuvel Pharmaceuticals Ltd (CUVL) submitted a Form 6-K as a foreign private issuer, forwarding materials it filed with the Australian Securities Exchange on August 27, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Clinuvel Pharmaceuticals Ltd (CUVL) submitted a Form 6-K as a foreign private issuer, forwarding materials it filed with the Australian Securities Exchange on August 27, 2026. The submission packages the company’s annual report, corporate governance disclosures, an Appendix 4G, an investor presentation, and several press releases as exhibits.

Key Terms

foreign private issuer, Form 20-F, Corporate Governance Disclosure, Appendix 4G

4 terms

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover of Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

Corporate Governance Disclosure regulatory

"99.2 | | Corporate Governance Disclosure"

Appendix 4G regulatory

"99.3 | | Appendix 4G - Key to Disclosures Corporate Governance Council"

FAQ

What is the purpose of Clinuvel Pharmaceuticals Ltd (CUVL) Form 6-K filed in August 2026?

The Form 6-K furnishes ASX-filed materials to U.S. investors, including the annual report, corporate governance disclosures, an Appendix 4G, an investor presentation, and three press releases, all dated around August 27, 2026.

Which key documents did CUVL include with this Form 6-K?

Clinuvel included its Annual Report (Exhibit 99.1), Corporate Governance Disclosure (99.2), Appendix 4G (99.3), an investor Presentation (99.4), and three press releases (99.5–99.7).

What is Clinuvel Pharmaceuticals Ltd’s reporting status in this Form 6-K?

Clinuvel is identified as a foreign private issuer and indicates that it files annual reports under cover of Form 20-F, rather than Form 40-F.

Who signed Clinuvel Pharmaceuticals Ltd’s August 2026 Form 6-K?

The Form 6-K was signed on behalf of Clinuvel Pharmaceuticals Ltd by Philippe Wolgen, who is identified as the company’s Managing Director and Chief Executive Officer.

Does this CUVL Form 6-K itself provide financial results?

The Form 6-K itself does not detail financial results; it forwards the Annual Report and related ASX documents as exhibits for investors seeking financial and corporate governance information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/27/2026 - 11:37 AM Accepted by SEC EDGAR 08/27/2026 - 11:35 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-43353

CLINUVEL PHARMACEUTICALS LIMITED

Level 22, 535 Bourke Street

Melbourne, VIC 3000

Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 27, 2026, Clinuvel Pharmaceuticals Limited filed various documents with the Australian Securities Exchange, a copy of each of which are attached as exhibits to this Form 6-K.

Exhibits

Exhibit No.		Description

99.1		Annual Report
99.2		Corporate Governance Disclosure
99.3		Appendix 4G - Key to Disclosures Corporate Governance Council Principles and Recommendations
99.4		Presentation
99.5		Press release
99.6		Press release
99.7		Press release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CLINUVEL PHARMACEUTICALS LIMITED

Date: August 27, 2026	By:	/s/ Philippe Wolgen
	Name:	Philippe Wolgen
	Title:	Managing Director and Chief Executive Officer